% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • leonard_yun leonard_yun Mar 16, 2012 12:02 PM Flag

    Synta vs Pharmasset

    With pipeline drying up, big pharmas are actually desperate looking for new drugs and willing to pay big as early as possible, and recent $11 billion buyout of Pharmasset's Phase II anti-HCV drug by Gilead is a good example. If you are familiar with cancer and hsp90 (a relatively new and less-known but well-validated anti-cancer target) and HCV fields, it's not difficult to find that today's Synta is more like yesterday's Pharmasset in many aspects. Yes, cancer is quite different from HCV, actually a cancer drug might get FDA approval easier and faster than a HCV one due to cancer drugs' relatively lower criteria of tolerable toxicity (lower benefit-risk bar from FDA) and potency expectation (usually a few weeks/months survival improvement than old drugs could do might be good enough to win FDA approval for many deadly cancers).

0.28+0.02(+7.49%)Jun 28 4:00 PMEDT